Werfen has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Aptiva Connective Tissue Disease (CTD) Essential reagent.

A fully automated multi-analyte system, Aptiva utilises particle-based multi-analyte technology, which processes several analytes simultaneously from the sample of a single patient.

Aptiva CTD Essential reagent can deliver up to 600 results per hour, thereby allowing the laboratory to complete test volumes with minimal hands-on time.

It also represents the next generation of high-throughput systems designed for use in the clinical autoimmune laboratory, the company claims.

Werfen research and business development vice-president Michael Mahler said: “Aptiva CTD Essential, with its unique biomarker composition and high level of analytical and clinical performance, represents a breakthrough that fundamentally enhances the utility of diagnostic testing in the autoimmune laboratory.

“We are excited to bring this latest expansion of the Aptiva reagent menu to the US market, resulting in advanced patient care.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aptiva CTD Essential reagent complements the company’s Aptiva Celiac Disease reagent, which was cleared previously.

Besides CTD and Celiac Disease assays, Aptiva will target further autoimmune disease states and has over 60 analytes in different stages of advanced development.

These analytes have the potential to cut down on the time to diagnosis of autoimmune diseases and help in the better management of patients.